

Nadunolimab

Cat. No.:	HY-P99235
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Nadunolimab is a human monoclonal IgG1 antibody targeting IL1RAP. Nadunolimab blocks IL-1 α and IL-1 β signaling and triggering antibody-dependent cellular cytotoxicity. Nadunolimab can be used in research of cancer ^[1] .	
IC₅₀ & Target	IL-1 α	IL-1 β
In Vitro	Nadunolimab (20 μ g/mL; 30 min and 1 h; A549 cells and BxPC3 cells) reduces IL-1 α -induced release of pro-inflammatory cytokines and chemokines, including IL-1 β , IL-6 TNF- α and MIP-1 α , and CXCL1 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Nadunolimab (10 mg/kg; i.p.; twice on day 1 and thereafter twice weekly; nude BALB/c mice with LU2503 or MC38 tumors) improves the anti-tumor efficacy of chemotherapy and blocks both murine IL-1 α and IL-1 β signaling ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Nude BALB/c mice with LU2503 or MC38 tumors ^[1]
	Dosage:	10 mg/kg
	Administration:	Intraperitoneal injection; twice on day 1 and thereafter twice weekly
	Result:	Reduced tumor volume in combination with Cisplatin (HY-17394) and Gemcitabine (HY-17026). Blocked both murine IL-1 α and IL-1 β signaling.

REFERENCES

[1]. Rydberg Millrud C, et, al. Blockade of IL-1 α and IL-1 β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol Immunother. 2022 Aug 29.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA